专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07550565B2 G-CSF conjugates 失效
标题翻译： G-CSF缀合物
公开(公告)号：US07550565B2
公开(公告)日：2009-06-23
申请号：US11463861
申请日：2006-08-10
申请人： Torben Lauesgaard Nissen , Kim Vilbour Andersen , Christian Karsten Hansen , Jan Moller Mikkelsen , Hans Thalsgaard Schambye
发明人： Torben Lauesgaard Nissen , Kim Vilbour Andersen , Christian Karsten Hansen , Jan Moller Mikkelsen , Hans Thalsgaard Schambye
IPC分类号： C07K14/535 , A61K38/00 , C07K1/107
CPC分类号： C07K14/53 , A61K47/60
摘要： Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.
摘要翻译：具有G-CSF活性的多肽缀合物包含与人G-CSF序列相比具有至少一个引入的赖氨酸残基和至少一个去除的赖氨酸残基的多肽，并与2-6个聚乙二醇部分缀合。缀合物具有低的体外生物活性，长的体内半衰期，减少的受体介导的清除，并且提供比非共轭重组人G-CSF更快速地刺激白细胞和嗜中性粒细胞的产生。

2. 发明授权

US07427592B2 Factor VII or VIIa - like molecules 有权
标题翻译：因子VII或VIIa样分子
公开(公告)号：US07427592B2
公开(公告)日：2008-09-23
申请号：US11423665
申请日：2006-06-12
申请人： Anders Hjelholt Pedersen , Kim Vilbour Andersen , Claus Bornaes
发明人： Anders Hjelholt Pedersen , Kim Vilbour Andersen , Claus Bornaes
IPC分类号： A61K38/35
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
摘要翻译：提供因子VII（FVII）和因子VIIa（FVIIA）的缀合物，以及制备它们的方法。提供了有助于制备这种缀合物的新型多肽的制备方法。提供了通过施用FVII或FVIIa缀合物治疗的方法。

3. 发明申请

US20070224635A1 Regulated Stop Codon Readthrough 审中-公开
标题翻译：监管停止密码子阅读
公开(公告)号：US20070224635A1
公开(公告)日：2007-09-27
申请号：US10587804
申请日：2005-01-28
申请人： Thomas Bouquin
发明人： Thomas Bouquin
IPC分类号： C12Q1/02 , C07H15/00 , C07H21/00 , G01N33/53 , C12N5/00 , C12P21/00
CPC分类号： C12N15/1086 , C07K2319/035 , C07K2319/40 , C07K2319/60 , C12N15/62 , C12N15/67 , G01N33/502
摘要： Methods for screening or selecting cells expressing a polypeptide of interest, e.g. for selecting cells expressing a desired level of a polypeptidé of interest, for evaluating recombinant polypeptide expression in a population of cells, or for selecting cells expressing a polypeptide with a desired binding affinity to a ligand, as well as for producing a polypeptide of interest from a selected cell, where the cells comprise an expression cassette comprising a first polynucleotide encoding the polypeptide of interest, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon, and where the cells are cultured in the presence of a termination suppression agent, in particular an aminoglycoside antibiotic, that results in regulated stop codon readthrough.
摘要翻译：用于筛选或选择表达目的多肽的细胞的方法，例如用于选择表达期望水平的感兴趣多肽的细胞，用于评估细胞群体中的重组多肽表达，或用于选择表达具有对配体的所需结合亲和力的多肽的细胞，以及用于产生感兴趣的多肽选择的细胞，其中细胞包含表达盒，其包含编码目标多肽的第一多核苷酸，第一多核苷酸下游的至少一个终止密码子，以及编码细胞膜锚定肽，报告肽或表位标签的第二多核苷酸在终止密码子的下游，并且其中细胞在终止抑制剂（特别是氨基糖苷类抗生素）存在下培养，导致调节的终止密码子读取。

4. 发明授权

US07226999B2 Protein C or activated protein C-like molecules 失效
标题翻译：蛋白C或活化蛋白C样分子
公开(公告)号：US07226999B2
公开(公告)日：2007-06-05
申请号：US11004111
申请日：2004-12-03
申请人： Kim Vilbour Andersen , Anders Hjelholt Pedersen , Per Ola Freskgaard
发明人： Kim Vilbour Andersen , Anders Hjelholt Pedersen , Per Ola Freskgaard
IPC分类号： A61K35/14 , A61K38/48 , C07K14/00
CPC分类号： C12N9/6464 , C12Y304/21069
摘要： The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and α1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.
摘要翻译：本发明涉及蛋白质C的多肽变体与非多肽部分如PEG或糖部分之间的新型缀合物。特别地，本发明提供了新的蛋白质C缀合物，其具有增强的抗失活能力。人血浆和α1 - 抗胰蛋白酶。因此，这种缀合物具有增加的体内半衰期。优选的实例包括蛋白质C缀合物，其中已经引入至少一个额外的体内N-糖基化位点。本发明的缀合物可用于治疗各种疾病，包括败血性休克。

5. 发明申请

US20060270703A1 G-CSF CONJUGATES 审中-公开
公开(公告)号：US20060270703A1
公开(公告)日：2006-11-30
申请号：US11462353
申请日：2006-08-03
申请人： Torben Nissen , Kim Andersen , Christian Hansen , Jan Mikkelsen , Hans Schambye
发明人： Torben Nissen , Kim Andersen , Christian Hansen , Jan Mikkelsen , Hans Schambye
IPC分类号： A61K31/70 , A61K31/44 , A01N43/04 , A01N43/42
CPC分类号： C07K14/535 , A61K9/0019 , A61K38/00 , A61K47/42 , A61K47/60 , A61K47/61 , C07K14/53
摘要： The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.

6. 发明申请

US20060228782A1 Factor VII or VIIa - Like Molecules 有权
公开(公告)号：US20060228782A1
公开(公告)日：2006-10-12
申请号：US11423622
申请日：2006-06-12
申请人： Anders Pedersen , Kim Andersen , Claus Bornaes
发明人： Anders Pedersen , Kim Andersen , Claus Bornaes
IPC分类号： A61K38/36 , C07H21/04 , C12P21/04 , C07K14/745
CPC分类号： C07K14/745 , A61K38/00 , A61K47/60 , A61K47/62 , C12N9/6437 , C12Y304/21021 , Y10S514/802
摘要： Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

7. 发明申请

US20060111282A1 Factor vii or viia polypeptide variants 有权
标题翻译：因子vii或viia多肽变体
公开(公告)号：US20060111282A1
公开(公告)日：2006-05-25
申请号：US10512754
申请日：2003-04-29
申请人： Jesper Haaning , Kim Andersen
发明人： Jesper Haaning , Kim Andersen
IPC分类号： A61K38/37
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
摘要翻译：本发明涉及因子VII（FVII）或因子VIIa（FVIIa）多肽的新型多肽变体，其中所述变体包含位置10和32的氨基酸取代，并且其中所述变体还包含共价连接到引入位于Gla结构域之外的体内N-糖基化位点。这样的多肽变体可用于治疗，特别是用于治疗各种凝血相关疾病如创伤。

8. 发明申请

US20060084793A1 G-CSF polypeptides and conjugates 审中-公开
公开(公告)号：US20060084793A1
公开(公告)日：2006-04-20
申请号：US11196846
申请日：2005-08-03
申请人： Torben Nissen , Kim Andersen , Christian Hansen , Jan Mikkelsen , Hans Schambye
发明人： Torben Nissen , Kim Andersen , Christian Hansen , Jan Mikkelsen , Hans Schambye
IPC分类号： C07K14/54
CPC分类号： A61K9/0019 , A61K38/00 , A61K47/42 , C07K14/535
摘要： The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.

9. 发明申请

US20050249703A1 Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression 失效
标题翻译：编码S99T干扰素γ多肽变体的多核苷酸和表达手段
公开(公告)号：US20050249703A1
公开(公告)日：2005-11-10
申请号：US11158848
申请日：2005-06-22
申请人： Anne Jensen
发明人： Anne Jensen
IPC分类号： A61K38/00 , C07K14/57 , C07H21/04 , C12N15/00 , C12N15/09
CPC分类号： C07K14/57 , A61K38/00
摘要： The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the polypeptide variants and their use in the treatment of diseases, in particular for the treatment of interstitial pulmonary diseases, such as idiopathic pulmonary fibrosis. These novel polypeptide variants all comprise the substitution S99T as compared to the amino acid sequence of huIFNG or fragments thereof. By performing this mutation the naturally occurring N-glycosylation site present at position 97 is significantly better utilized. Preferably, the variants comprise further modifications, e.g. in order to increase the AUC of such variants when administered subcutaneously.
摘要翻译：本发明涉及具有干扰素γ（IFNG）活性的新型干扰素γ多肽变体，其制备方法，包含多肽变体的药物组合物及其在治疗疾病中的用途，特别是用于治疗间质性肺疾病，例如特发性肺纤维化。与huIFNG或其片段的氨基酸序列相比，这些新型多肽变体全部包含取代S99T。通过进行该突变，存在于位置97处的天然存在的N-糖基化位点被显着地更好地利用。优选地，变体包括进一步的修饰，例如。以便在皮下施用时增加这些变体的AUC。

10. 发明授权

US06933367B2 Protein C or activated protein C-like molecules 失效
标题翻译：蛋白C或活化蛋白C样分子
公开(公告)号：US06933367B2
公开(公告)日：2005-08-23
申请号：US09997623
申请日：2001-11-29
申请人： Kim Vilbour Andersen , Anders Hjelholt Pedersen , Per Ola Freskgaard
发明人： Kim Vilbour Andersen , Anders Hjelholt Pedersen , Per Ola Freskgaard
IPC分类号： C12N9/64 , A61K35/14 , A61K38/48 , C07K14/00
CPC分类号： C12N9/6464 , C12Y304/21069
摘要： The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and α1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.
摘要翻译：本发明涉及蛋白质C的多肽变体与非多肽部分如PEG或糖部分之间的新型缀合物。特别地，本发明提供了新的蛋白质C缀合物，其具有增强的抗失活能力。人血浆和α1 - 抗胰蛋白酶。因此，这种缀合物具有增加的体内半衰期。优选的实例包括蛋白质C缀合物，其中已经引入至少一个额外的体内N-糖基化位点。本发明的缀合物可用于治疗各种疾病，包括败血性休克。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式